Addex Therapeutics Ltd (ADXN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.3900 |
| Open | 1.3600 |
| Bid | 1.3500 x 1300 |
| Ask | 1.3800 x 800 |
| Day's Range | 1.3000 - 1.4300 |
| 52 Week Range | 0.8600 - 10.2800 |
| Volume | |
| Avg. Volume | 2,996,603 |
| Market Cap | 7.713M |
| Beta (5Y Monthly) | 1.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6580 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
Addex to Receive CHF850,000 ($900,000) of Additional Funding; Addex’s Reserved Indications Expanded to include Chronic Cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its collaboration agreement with Indivior PLC (LON: INDV) for discovering and developing novel oral gamma-aminobutyric
- GlobeNewswire
Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022
Geneva, Switzerland, August 12, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2022 financial results on Thursday, August 18, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title: Addex Thera
- GlobeNewswire
Addex Completes $4.2 Million Equity Financing
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 26, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has completed an equity financing transaction entered into on July 22, 2022 with Armistice Master Fund Ltd. (“Armistice”), a healthcare-focused institutional investor, pursuant to which the Company sold 4,500,000 shares in the form
